Seth Lewis, MD
Internal Medicine · Ogden, UTNPI 1851409544
Payments from drug & device makers
Across 131 payments — averaging $13.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$446
- AbbVie$297
- Astellas Pharma US Inc$170
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$160
- E.r. Squibb & Sons, L.L.C.$120
- Lilly USA, LLC$113
- plus $516 from 15 others
What the payments were for
- Food & beverage$1,821100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 28 | $446 |
| AbbVie(2 entities) | 25 | $297 |
| Astellas Pharma US Inc | 10 | $170 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 19 | $160 |
| E.r. Squibb & Sons, L.L.C. | 7 | $120 |
| Lilly USA, LLC | 7 | $113 |
| Pfizer | 6 | $101 |
| Merck | 5 | $69 |
| Novartis | 4 | $63 |
| Amgen | 4 | $59 |
| Johnson & Johnson | 3 | $51 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $33 |
| Eisai Inc. | 2 | $28 |
| Sumitomo Pharma America, Inc. | 2 | $18 |
| Bayer | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Novo Nordisk | 1 | $14 |
| Baxter Healthcare | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
| GSK | 1 | $12 |
| AstraZeneca | 1 | $11 |
How this compares
$1,821 in reported general payments places this provider in the 75th percentile of 496 internal medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 124 | $179,308 |
| EliquisApixaban | 113 | $113,930 |
| TrulicityDulaglutide | 41 | $54,143 |
| JardianceEmpagliflozin | 27 | $37,583 |
| XareltoRivaroxaban | 25 | $25,367 |
| MyrbetriqMirabegron | 24 | $20,111 |
| Breo ElliptaFluticasone/Vilanterol | 29 | $16,110 |
| GemtesaVibegron | 11 | $14,629 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 11 | $14,035 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $13,007 |
| Repatha SureclickEvolocumab | 18 | $12,595 |
| FarxigaDapagliflozin Propanediol | 14 | $12,399 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $8,346 |
| Novolog FlexpenInsulin Aspart | 17 | $7,100 |
| BelsomraSuvorexant | 16 | $7,036 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $113 | $233,452165 claims |
| PfizerEliquis | $101 | $113,930113 claims |
| Boehringer IngelheimJardiance | $446 | $37,58327 claims |
| Johnson & JohnsonXarelto | $51 | $25,36725 claims |
| GSKBreo Ellipta, Anoro Ellipta | $12 | $24,45643 claims |
| Astellas Pharma US IncMyrbetriq | $170 | $20,11124 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $18 | $14,62911 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $12 | $14,03511 claims |
| AstraZenecaFarxiga | $11 | $12,39914 claims |
| MerckBelsomra | $69 | $7,03616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 496 internal medicine providers in Utah.
Other internal medicine in Ogden
- Justin MansfieldOgden$3.1M
- Elena GoncharovaOgden$202K
- Celine RiveraOgden$11K
- Matthew ReddOgden$8K
- Scott MoultonOgden$7K
- Donna MilavetzOgden$7K
- Robert MohrOgden$7K
- Ahad SabetSalt Lake City$34.5M
- Barbara RizzardiSandy$27.8M
- Willard DereSalt Lake City$4.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.